How is hepatorenal syndrome diagnosed and managed in a patient with advanced cirrhosis and portal hypertension?

Hepatorenal Syndrome: Diagnosis and Management

Diagnostic Confirmation

Hepatorenal syndrome (HRS) is diagnosed when a cirrhotic patient with ascites develops acute kidney injury that fails to improve after 2 consecutive days of diuretic withdrawal and albumin volume expansion (1 g/kg up to 100 g on day 1), in the absence of shock, nephrotoxic drugs, or structural kidney disease. 1, 2

Required Diagnostic Criteria (All Must Be Present)

• Cirrhosis with ascites 1, 3
• Acute kidney injury defined by creatinine increase ≥0.3 mg/dL within 48 hours or ≥50% from baseline 3, 4
• No improvement after 2 days of diuretic withdrawal and albumin expansion (1 g/kg, maximum 100 g) 1, 2, 4
• Absence of shock 1, 3
• No nephrotoxic drug exposure (NSAIDs, aminoglycosides, contrast media) 3, 4
• No structural kidney disease: proteinuria <500 mg/day, microhematuria <50 RBCs/HPF, normal renal ultrasound 1, 3, 4

Critical First Step: Rule Out Precipitants

• Perform diagnostic paracentesis immediately to exclude spontaneous bacterial peritonitis (SBP), which precipitates HRS in ~30% of cases and requires specific treatment with antibiotics plus albumin 2, 4
• Check for gastrointestinal bleeding, volume depletion from aggressive diuresis, or large-volume paracentesis without albumin replacement 4

AKI Staging (Use Dynamic Criteria, Not Fixed Thresholds)

• Stage 1: Creatinine increase ≥0.3 mg/dL or 1.5-2× baseline 2, 3
• Stage 2: Creatinine 2-3× baseline 2, 3
• Stage 3: Creatinine >3× baseline or >4 mg/dL with acute increase ≥0.3 mg/dL, or initiation of renal replacement therapy 2, 3

Critical pitfall: Do not wait for creatinine to reach 1.5 mg/dL before considering HRS—the fixed threshold has been abandoned because it delays diagnosis and worsens outcomes. 4

---

Management Algorithm

Step 1: Immediate Referral for Liver Transplantation

All patients with HRS-AKI (Type 1 HRS) should receive expedited referral for liver transplantation, as this is the only definitive treatment with ~65% survival. 2, 5 Median survival of untreated Type 1 HRS is approximately 1 month. 3, 4

Step 2: First-Line Pharmacologic Treatment

Terlipressin plus albumin is the first-line pharmacological treatment for HRS-AKI, achieving reversal in 64-76% of patients. 2

Terlipressin + Albumin Regimen

• Initial dose: Terlipressin 1 mg IV bolus every 4-6 hours plus albumin 1 g/kg (maximum 100 g) on day 1, then 20-40 g/day 2
• Dose escalation: If creatinine has not decreased ≥25% by day 3-4, increase terlipressin to 2 mg IV every 4 hours (maximum 12 mg/day) 2
• Alternative dosing: Continuous IV infusion of terlipressin 2 mg/day reduces total dose and adverse events compared to bolus dosing 2
• Treatment duration: Continue until creatinine ≤1.5 mg/dL or maximum 14 days; median time to response is 14 days 2

Predictors of Favorable Response

• Baseline creatinine <3 mg/dL 2
• Bilirubin <10 mg/dL 2
• MAP increase ≥5 mmHg during therapy 2
• Lower MELD score and Child-Pugh <13 2
• Younger age 2

Absolute Contraindications to Terlipressin

Terlipressin is absolutely contraindicated in active coronary, peripheral, or mesenteric ischemia. 2 Obtain baseline ECG before initiation. 2 Common ischemic adverse effects include angina, arrhythmias, and digital ischemia. 2

Step 3: Alternative Vasoconstrictor Regimens

When Terlipressin Is Unavailable or Contraindicated

Norepinephrine 0.5-3 mg/hour continuous IV infusion plus albumin is equally effective to terlipressin but requires ICU-level monitoring with central venous access. 2

• Starting dose: 0.5 mg/hour IV, titrate every 4 hours to raise MAP by 10-15 mmHg 2
• Critical requirement: Central venous access mandatory; peripheral administration risks tissue necrosis 2
• Goal: Increase MAP by 15 mmHg 1, 2

For Patients With Ischemic Heart Disease

In patients with known ischemic heart disease, midodrine plus octreotide plus albumin is the preferred regimen because terlipressin is contraindicated. 2

• Midodrine: 7.5-12.5 mg orally three times daily 2
• Octreotide: 100-200 μg subcutaneously three times daily 2
• Albumin: 10-20 g IV daily for up to 20 days 2
• Important caveat: Efficacy is substantially lower than terlipressin-based regimens 2

Step 4: Monitoring During Vasoconstrictor Therapy

• Serum creatinine every 2-3 days to assess renal response 2
• Mean arterial pressure: Target increase of 10-15 mmHg 2
• Heart rate: Expect decrease of ~10 beats/min with terlipressin 2
• Central venous pressure (when available) to guide fluid balance and avoid overload 2
• Urine output and serum sodium should rise with effective treatment 2
• Watch vigilantly for pulmonary edema, especially in patients with underlying cardiac dysfunction 2

Step 5: Transjugular Intrahepatic Portosystemic Shunt (TIPS)

TIPS is more suitable for Type 2 HRS (HRS-NAKI) because patients are clinically more stable; it improves renal function and ascites control. 2, 6

Contraindications to TIPS

• Severe hepatic dysfunction (bilirubin >5 mg/dL) 2
• High MELD score 2
• Significant renal dysfunction 2
• Cardiac failure 2
• Clinically significant hepatic encephalopathy 2

Small studies suggest TIPS may benefit Type 1 HRS, but its use is limited by advanced liver failure. 2

Step 6: Renal Replacement Therapy (RRT)

Initiate RRT based on clinical indications: refractory electrolyte/acid-base disturbances, refractory volume overload, symptomatic azotemia, or worsening renal function despite vasoconstrictors. 2

• RRT is primarily a bridge to liver transplantation; outcomes in critically ill cirrhotic patients requiring RRT remain poor with high mortality 2
• Continuous venovenous hemofiltration/hemodialysis causes less hypotension than intermittent hemodialysis but requires continuous dialysis nurse involvement 1

---

Prevention Strategies

SBP Prophylaxis

Administer albumin 1.5 g/kg at SBP diagnosis, then 1 g/kg on day 3; this reduces HRS incidence from ~30% to ~10% and mortality from ~29% to ~10%. 2, 3

Post-Paracentesis Albumin

For large-volume paracentesis (>5 L), administer IV albumin 6-8 g per liter of ascitic fluid removed to prevent post-paracentesis circulatory dysfunction and HRS. 2

Antibiotic Prophylaxis

• Provide antibiotic prophylaxis for 7 days after gastrointestinal bleeding 2
• Norfloxacin 400 mg/day reduces HRS incidence in advanced cirrhosis with low ascitic fluid protein 2, 3
• Pentoxifylline 400 mg three times daily for 4 weeks prevents HRS in severe alcoholic hepatitis 2, 3

---

Management of Recurrent HRS

If HRS-AKI recurs after stopping therapy, repeat a course of vasoconstrictor treatment. 2 However, vasoconstrictors and albumin are not recommended for HRS-NAKI (Type 2 HRS) outside the AKI criteria, as recurrence after withdrawal is common and long-term outcome data are inconclusive. 2

---

Critical Pitfalls to Avoid

• Do not delay treatment: Early initiation of vasoconstrictors after HRS-AKI diagnosis improves outcomes, especially before progression to higher ACLF grades 2, 4
• Do not omit albumin: Albumin is essential for volume expansion and anti-inflammatory effects 2
• Do not persist with ineffective therapy: If creatinine fails to decrease ≥25% after 3-4 days despite dose escalation, consider alternative vasoconstrictors, RRT, or transplantation 2
• Do not overlook precipitating factors: Always rule out and treat SBP, gastrointestinal bleeding, and discontinue nephrotoxic drugs 2, 4
• Do not use urine output as a diagnostic criterion in cirrhotic patients with ascites 4
• Do not wait for creatinine >1.5 mg/dL—use dynamic AKI criteria instead 4

---

Prognosis and Transplantation Considerations

The development of ascites reduces 5-year survival from 80% to 30%, and patients with HRS have a median survival of approximately 1 month without treatment. 1, 3 Treatment of HRS with vasoconstrictors before transplantation may improve post-transplant outcomes, and HRS reverses in approximately 75% of patients after liver transplantation alone. 2 However, the reduction in serum creatinine and MELD score after treatment should not change the decision to perform liver transplantation, since prognosis after recovering from HRS remains poor. 2